Molbio Diagnostics has debuted at Rs 980.00 on the BSE, up by 173.00 points or 21.44% from its issue price of Rs 807.
The scrip is currently trading at Rs. 1018.00, up by 211.00 points or 26.15% from its issue price.
It has touched a high and low of Rs. 1,044.75 and Rs. 925.80 respectively. So far 11.54 lakh shares were traded on the counter.
The offering, which was open for subscription August 10, 2026 and August 12, 2026 was subscribed 70.27 times. The issue price was fixed at Rs 807 per share i.e. at upper end of price band of Rs 768 - 807 apiece.
Molbio Diagnostics is an innovative point-of-care diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases.
| Company Name | CMP |
|---|---|
| Lenskart Solutions | 643.25 |
| Poly Medicure | 1776.95 |
| Molbio Diagnostics | 1067.25 |
| Laxmi Dental | 202.30 |
| Nureca | 313.40 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: